An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies.
Despite the discovery more than two decades ago that antisense oligonucleotides (ASOs) could be used to modulate protein expression, there have been only two antisense drugs approved for clinical use till date. Despite this low success rate, the antisense field is undergoing resurgence due to the development of more potent and nuclease resistant chemistries, as well as nanoparticle delivery systems that enhance delivery to target tissues. In this review, we introduce the predominant therapeutic strategies in the antisense field whilst highlighting recent clinical findings that demonstrate the significant potential of these approaches for development of novel therapies in several diseases.
Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, OX1 3QX Oxford, UK.
Graham
G
McClorey
Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, OX1 3QX Oxford, UK. Electronic address: matthew.wood@dpag.ox.ac.uk.
Matthew J
MJ
Wood
D000818:Animals; D015870:Gene Expression; D006801:Humans; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D012313:RNA / Q000235:genetics*; D012326:RNA Splicing
D016376:Oligonucleotides, Antisense; D012313:RNA